美沙拉嗪与双歧杆菌三联活菌联合治疗溃疡性结肠炎的疗效
|
摘要
目的探讨美沙拉嗪与双歧杆菌三联活菌联合治疗溃疡性结肠炎的疗效。方法收集2016年1月—2018年3月我院收治的溃疡性结肠炎患者93例作为研究对象,按治疗方法分组,研究组46例,给予美沙拉嗪与双歧杆菌三联活菌胶囊联合治疗,对照组47例,给予美沙拉嗪治疗,两组均连续治疗2个月。比较临床疗效、UCDAI、IL-6、IL-8、TNF-α及不良反应情况。结果研究组治疗总有效率更高,差异有统计学意义(P <0.05)。治疗后两组UCDAI均明显低于治疗前,研究组(3.63±0.47)分,低于对照组的(5.07±0.89)分,差异有统计学意义(P <0.05)。治疗后两组IL-6、IL-8、TNF-α均低于治疗前,研究组IL-6、IL-8、TNF-α[(97.2±18.5)ng/L、(147.5±23.6)ng/L、(80.6±14.2)ng/L]与同期对照组比较更低,差异有统计学意义(P <0.05)。研究组不良反应发生率(8.70%)与对照组比较差异无统计学意义(P> 0.05)。结论美沙拉嗪与双歧杆菌三联活菌联合治疗溃疡性结肠炎效果显著,可使临床症状显著改善,血清促炎细胞因子水平有效下调,安全性高。
Objective To investigate the efficacy of mesalazine combined with Bifidobacterium triple live bacteria in the treatment of ulcerative colitis. Methods 93 patients with ulcerative colitis admitted to our hospital from January 2016 to March 2018 were enrolled in the study. According to the treatment, they were divided into two groups, there were 46 patients in the study group and were treated with combination of mesalazine and bifidobacteria triple live capsule. 47 patients in the control group were treated with mesalazine, and both groups were treated continuously for2 months. The clinical efficacy, UCDAI, IL-6, IL-8, TNF-α and adverse reactions of two groups were compared. Results The total effective rate of the study group was higher, and the difference was statistically significant(P < 0.05). After treatment, the UCDAI of the two groups was significantly lower than that before treatment. The study group(3.63±0.47) was lower than the control group(5.07±0.89), and there was significant difference between two groups(P < 0.05). After treatment, IL-6, IL-8 and TNF-α were lower than those before treatment. The study group IL-6, IL-8, TNF-α[(97.2±18.5)ng/L,(147.5±23.6)ng/L,(80.6±14.2)ng/L] were lower than the same period of control the group, and there were significant difference between two groups(P < 0.05). There were no significant difference in the incidence of adverse reactions between the study group and the control group(P > 0.05). Conclusion The combination of mesalazine and bifidobacteria in the treatment of ulcerative colitis has a significant effect,which can significantly improve clinical symptoms, effectively reduce serum pro-inflammatory cytokine levels, and have high safety.
Objective To investigate the efficacy of mesalazine combined with Bifidobacterium triple live bacteria in the treatment of ulcerative colitis. Methods 93 patients with ulcerative colitis admitted to our hospital from January 2016 to March 2018 were enrolled in the study. According to the treatment, they were divided into two groups, there were 46 patients in the study group and were treated with combination of mesalazine and bifidobacteria triple live capsule. 47 patients in the control group were treated with mesalazine, and both groups were treated continuously for2 months. The clinical efficacy, UCDAI, IL-6, IL-8, TNF-α and adverse reactions of two groups were compared. Results The total effective rate of the study group was higher, and the difference was statistically significant(P < 0.05). After treatment, the UCDAI of the two groups was significantly lower than that before treatment. The study group(3.63±0.47) was lower than the control group(5.07±0.89), and there was significant difference between two groups(P < 0.05). After treatment, IL-6, IL-8 and TNF-α were lower than those before treatment. The study group IL-6, IL-8, TNF-α[(97.2±18.5)ng/L,(147.5±23.6)ng/L,(80.6±14.2)ng/L] were lower than the same period of control the group, and there were significant difference between two groups(P < 0.05). There were no significant difference in the incidence of adverse reactions between the study group and the control group(P > 0.05). Conclusion The combination of mesalazine and bifidobacteria in the treatment of ulcerative colitis has a significant effect,which can significantly improve clinical symptoms, effectively reduce serum pro-inflammatory cytokine levels, and have high safety.
引文
[1]高孟耐,周浩,余祝,等.马来酸曲美布汀片对溃疡性结肠炎患者血清TNF-α、IL-23、ESR、D-D的影响[J].中国生化药物杂志,2017,37(4):204-206.
[2]李习忠.益生菌联合美沙拉嗪治疗溃疡性结肠炎的效果观察[J].河南医学研究,2017,26(23):4303-4304.
[3]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见(2007年,济南)[J].中华消化杂志,2007,27(8):545-550.
[4]韩英,韩者艺,郭学刚,等.奥沙拉嗪与SASP灌肠治疗溃疡性结肠炎的疗效对比观察[J].胃肠病学和肝病学杂志,2006,15(2):152-154.
[5]涂静,赵太云,闫碧春,等.丙氨酰谷氨酰胺对溃疡性结肠炎患者疗效及其血清炎症因子的影响研究[J].临床和实验医学杂志,2018,17(16):1736-1738.
[6]焦健,郑红蕾.美沙拉嗪与康复新液联合保留灌肠治疗溃疡性结肠炎的疗效观察[J].云南医药,2015,36(3):308-309.
[7]庞智,李宁,丁海燕,等.益生菌联合美沙拉秦治疗溃疡性结肠炎的疗效和安全性观察[J].中国微生态学杂志,2016,28(1):41-46.
[8]陈赞青.双歧三联活菌合柳氮磺吡啶治疗溃疡性结肠炎52例临床观察[J].中国民族民间医药杂志,2015,24(22):73.
[9]唐学军,王小云,吴高珏.双歧杆菌三联活菌散辅助治疗溃疡性结肠炎对炎症因子及T淋巴细胞亚群的影响[J].海南医学院学报,2017,23(12):1620-1622,1626.
[10]邓台燕,全大祥,吴彬.复方黄柏液联合美沙拉嗪对溃疡性结肠炎及肠道菌群和血清炎症因子的影响[J].中国现代医学杂志,2016,26(9):124-127.
[11]贺佳玉,何咏梅.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎及对血清炎症因子的影响[J].四川医学,2015,36(6):854-857.
[12]戴欢.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效对比分析[J].中国继续医学教育,2017,9(9):196-198.
[13]赵冰.双歧三联活菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对血清炎症因子的影响[J].中国现代医药杂志,2016,18(5):65-67.
[2]李习忠.益生菌联合美沙拉嗪治疗溃疡性结肠炎的效果观察[J].河南医学研究,2017,26(23):4303-4304.
[3]中华医学会消化病学分会炎症性肠病协作组.对我国炎症性肠病诊断治疗规范的共识意见(2007年,济南)[J].中华消化杂志,2007,27(8):545-550.
[4]韩英,韩者艺,郭学刚,等.奥沙拉嗪与SASP灌肠治疗溃疡性结肠炎的疗效对比观察[J].胃肠病学和肝病学杂志,2006,15(2):152-154.
[5]涂静,赵太云,闫碧春,等.丙氨酰谷氨酰胺对溃疡性结肠炎患者疗效及其血清炎症因子的影响研究[J].临床和实验医学杂志,2018,17(16):1736-1738.
[6]焦健,郑红蕾.美沙拉嗪与康复新液联合保留灌肠治疗溃疡性结肠炎的疗效观察[J].云南医药,2015,36(3):308-309.
[7]庞智,李宁,丁海燕,等.益生菌联合美沙拉秦治疗溃疡性结肠炎的疗效和安全性观察[J].中国微生态学杂志,2016,28(1):41-46.
[8]陈赞青.双歧三联活菌合柳氮磺吡啶治疗溃疡性结肠炎52例临床观察[J].中国民族民间医药杂志,2015,24(22):73.
[9]唐学军,王小云,吴高珏.双歧杆菌三联活菌散辅助治疗溃疡性结肠炎对炎症因子及T淋巴细胞亚群的影响[J].海南医学院学报,2017,23(12):1620-1622,1626.
[10]邓台燕,全大祥,吴彬.复方黄柏液联合美沙拉嗪对溃疡性结肠炎及肠道菌群和血清炎症因子的影响[J].中国现代医学杂志,2016,26(9):124-127.
[11]贺佳玉,何咏梅.美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎及对血清炎症因子的影响[J].四川医学,2015,36(6):854-857.
[12]戴欢.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的疗效对比分析[J].中国继续医学教育,2017,9(9):196-198.
[13]赵冰.双歧三联活菌联合美沙拉嗪治疗溃疡性结肠炎的临床疗效及对血清炎症因子的影响[J].中国现代医药杂志,2016,18(5):65-67.